NCT01088789
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 29 versions: 17 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 20 words
- Trial completed
- Study completion date changed from estimate of Aug 2026 to Mar 2, 2026
- Secondary endpoints: 2 to 4
- Minor Study completion date: Aug 2025 to Aug 2026v28
- Minor Study completion date: Jul 2025 to Aug 2025v27
Notable Results first posted: Jul 3, 2025v26 Show 6 more changesShow less
- Primary endpoints: 1 to 2
- Interventions: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine. (Biological) to Cyclophosphamide (Drug), Cyclophosphamide Pill (Drug), GVAX Pancreas Vaccine (Biological)
- Secondary endpoints expanded, about 7 words
- Study description shortened, about 117 words
- Study arms: 5 to 7
- Study title expanded, about 3 words
- Minor Primary completion date changed from estimate of Aug 2024 to Jul 17, 2024
- Study completion date: Aug 2024 to Jul 2025
Show 11 earlier versionsHide 11 earlier versions
- Notable Primary and study completion dates: Aug 2023 to Aug 2024v22
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 72 to confirmed 71
- Primary and study completion dates: Apr 2023 to Aug 2023
- Site details revised
- Notable Eligibility criteria shortened, about 51 words
- Study description shortened, about 267 words
- Study arms: 3 to 5
- Minor Study description expanded, about 5 wordsv17
- Minor Start date: Apr 2010 to Apr 20, 2010
- Collaborators expanded, about 4 words
- Notable Eligibility criteria expanded, about 3 wordsv12
- Minor Enrollment target: 58 to 72v8
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study site revised
- Notable Enrollment target: 20 to 58
- Eligibility criteria expanded, about 42 words
- Study description expanded, about 55 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Patients coming from J0810 (NCT00727441). Patients receive GVAX.
Patients coming from J0810 (NCT00727441). Patients receive IV CY and GVAX.
Patients coming from J0810 (NCT00727441). Patients receive oral CY and GVAX.
Patients receive IV CY and GVAX.
Patients coming from J1568 (NCT02451982). Patients receive IV CY and GVAX.
Patients coming from J15237 (NCT02648282). Patients receive IV CY and GVAX.
Patients coming from J1766 (NCT03153410). Patients receive IV CY and GVAX.
Drugs: Cyclophosphamide, Cyclophosphamide Pill
Biologicals: GVAX Pancreas Vaccine
Sites
1 site in 1 country
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland, United States